JP5442179B2 - Method for suppressing sedimentation of fine particles bound with reactive substance and reagent containing the fine particles - Google Patents
Method for suppressing sedimentation of fine particles bound with reactive substance and reagent containing the fine particles Download PDFInfo
- Publication number
- JP5442179B2 JP5442179B2 JP2005307879A JP2005307879A JP5442179B2 JP 5442179 B2 JP5442179 B2 JP 5442179B2 JP 2005307879 A JP2005307879 A JP 2005307879A JP 2005307879 A JP2005307879 A JP 2005307879A JP 5442179 B2 JP5442179 B2 JP 5442179B2
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- bound
- sample
- concentration
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 169
- 238000000034 method Methods 0.000 title claims description 39
- 238000004062 sedimentation Methods 0.000 title claims description 38
- 239000000126 substance Substances 0.000 title description 75
- 239000010419 fine particle Substances 0.000 title description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 49
- 239000002245 particle Substances 0.000 claims description 32
- 229960000633 dextran sulfate Drugs 0.000 claims description 25
- 238000003018 immunoassay Methods 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000006185 dispersion Substances 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 66
- 239000011859 microparticle Substances 0.000 description 57
- 239000000523 sample Substances 0.000 description 56
- 238000005259 measurement Methods 0.000 description 49
- 238000002835 absorbance Methods 0.000 description 35
- 238000003756 stirring Methods 0.000 description 31
- 239000000243 solution Substances 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000001556 precipitation Methods 0.000 description 22
- 102000012192 Cystatin C Human genes 0.000 description 21
- 108010061642 Cystatin C Proteins 0.000 description 21
- 239000002202 Polyethylene glycol Substances 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 19
- 229920001223 polyethylene glycol Polymers 0.000 description 19
- 238000008416 Ferritin Methods 0.000 description 18
- 229920002307 Dextran Polymers 0.000 description 16
- 229960002086 dextran Drugs 0.000 description 16
- 229920000447 polyanionic polymer Polymers 0.000 description 16
- 102000008857 Ferritin Human genes 0.000 description 14
- 108050000784 Ferritin Proteins 0.000 description 14
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 14
- 229920000669 heparin Polymers 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 8
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 8
- 239000007995 HEPES buffer Substances 0.000 description 7
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 230000004520 agglutination Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229960001008 heparin sodium Drugs 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- -1 dextran sulfate Chemical compound 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 229920003045 dextran sodium sulfate Polymers 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102000023022 Pepsinogens Human genes 0.000 description 1
- 108010014475 Pepsinogens Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960004037 bromperidol Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- XBECFEJUQZXMFE-UHFFFAOYSA-N n-(4-aminobutyl)acetamide;hydrochloride Chemical compound Cl.CC(=O)NCCCCN XBECFEJUQZXMFE-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229960002796 polystyrene sulfonate Drugs 0.000 description 1
- 239000011970 polystyrene sulfonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- CBXWGGFGZDVPNV-UHFFFAOYSA-N so4-so4 Chemical compound OS(O)(=O)=O.OS(O)(=O)=O CBXWGGFGZDVPNV-UHFFFAOYSA-N 0.000 description 1
- 229940077386 sodium benzenesulfonate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- FBZONXHGGPHHIY-UHFFFAOYSA-N xanthurenic acid Chemical compound C1=CC=C(O)C2=NC(C(=O)O)=CC(O)=C21 FBZONXHGGPHHIY-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
本発明は、抗体または抗原などの反応性を有する物質が結合した微小粒子（以下、反応性物質結合微小粒子という）の沈降抑制方法および該反応性物質結合微小粒子を用いた免疫測定用試薬に関する。特に、主として臨床検査の分野で、抗原抗体反応を利用した免疫学的測定に用いられる反応性物質結合微小粒子の沈降抑制方法および該反応性物質結合微小粒子を用いた免疫測定用試薬に関する。 The present invention relates to a method for suppressing sedimentation of microparticles (hereinafter referred to as reactive substance-bound microparticles) to which a reactive substance such as an antibody or an antigen is bound, and an immunoassay reagent using the reactive substance-bound microparticles. . In particular, the present invention relates to a method for suppressing precipitation of reactive substance-bound microparticles used for immunological measurement utilizing antigen-antibody reaction mainly in the field of clinical tests, and an immunoassay reagent using the reactive substance-bound microparticles.
近年、臨床検査などの各種検査においては、自動化および測定時間の短縮化の観点から、免疫反応を利用して、生体試料中の物質を測定する方法が広く用いられている。この免疫測定方法としては、ＲＩＡ法、ＥＩＡ法、免疫比濁法、ラテックス凝集法、金コロイド凝集法、イムノクロマト法などが挙げられる。その中でも、ラテックス凝集法、金コロイド凝集法などの反応性を有する物質が結合した微小粒子（反応性物質結合微小粒子）を用いる方法は、反応液の分離や洗浄操作を必要としないため、特に測定の自動化や短時間化に適している。 In recent years, in various tests such as clinical tests, a method of measuring a substance in a biological sample using an immune reaction has been widely used from the viewpoint of automation and shortening of measurement time. Examples of the immunoassay method include RIA method, EIA method, immunoturbidimetric method, latex agglutination method, colloidal gold agglutination method, immunochromatography method and the like. Among them, the method using microparticles (reactive substance-binding microparticles) bonded with reactive substances such as latex agglutination method and gold colloid agglomeration method does not require separation or washing operation of the reaction solution. Suitable for automation and shortening of measurement.
しかし、これらのラテックス凝集法および金コロイド凝集法は、反応性物質結合微小粒子が沈降し易いため、使用時あるいは測定時に常に攪拌などによって、該微小粒子の濃度を均一化する必要があり、測定誤差を生じ易いという問題点がある。 However, in these latex agglomeration methods and colloidal gold agglomeration methods, reactive substance-bound microparticles tend to settle, so it is necessary to make the concentration of the microparticles uniform by stirring during use or measurement. There is a problem that an error is likely to occur.
例えば、上記方法に用いる試薬は、通常、試料の希釈、試料の本反応前の前処理、および本反応を補助する成分を主に含有する第一試薬と、主に反応に関与する主成分である反応性物質結合微小粒子を含有する第二試薬との２種から構成される。自動化分析装置を用いる場合は、まず、試料と第一試薬とを反応セルに分注し、続いて、一定時間経過後、反応セルに第二試薬を分注することによって、試料、第一試薬、および第二試薬の三者を混合して最終反応液を得、測定が行われる。この場合において、一旦、反応性物質結合微小粒子含有試薬（第二試薬）を分析装置にセットしても、一定期間ごとに第二試薬を攪拌し、濃度を均一にする必要があった。 For example, the reagents used in the above method are usually the first reagent mainly containing the dilution of the sample, the pretreatment before the main reaction of the sample, and the component assisting the main reaction, and the main component mainly involved in the reaction. It is composed of two types including a second reagent containing a certain reactive substance-bound microparticle. When using an automated analyzer, first, the sample and the first reagent are dispensed into the reaction cell, and after a certain period of time, the second reagent is dispensed into the reaction cell. , And the second reagent are mixed to obtain a final reaction solution, and measurement is performed. In this case, once the reactive substance-bound microparticle-containing reagent (second reagent) was set in the analyzer, it was necessary to stir the second reagent at regular intervals to make the concentration uniform.
従来、このような反応性物質結合微小粒子の沈降を抑制するための検討は行われていなかった。上記第一試薬、第二試薬および最終反応液の組成については、微小粒子の反応性の安定性の向上や反応促進の目的で改良がなされているのみである（例えば、特許文献１および２）。 Heretofore, no study has been conducted to suppress the sedimentation of such reactive substance-bound microparticles. The compositions of the first reagent, the second reagent, and the final reaction solution are only improved for the purpose of improving the stability of the reactivity of the microparticles and promoting the reaction (for example, Patent Documents 1 and 2). .
特許文献１には、感作金属コロイドの反応性を安定化させる方法として、感作金属コロイドを含有する溶液に、カルシウムイオン、マグネシウムイオン、およびバリウムイオンから選ばれる金属イオン、デキストラン硫酸、コール酸、デオキシコール酸、キサンツレン酸またはそれらの塩から選ばれる物質の１種または２種以上を含有させることが記載されている。 In Patent Document 1, as a method for stabilizing the reactivity of a sensitized metal colloid, a solution containing a sensitized metal colloid is added to a metal ion selected from calcium ions, magnesium ions, and barium ions, dextran sulfate, and cholic acid. , Deoxycholic acid, xanthurenic acid or a salt thereof is described to contain one or more substances.
特許文献２には、測定対象物質に対する抗体（または抗原）が結合した金コロイド粒子と測定物質とを反応させる溶液（最終反応液）中に、反応促進剤として、平均分子量が約２０，０００以上のポリアニオンまたはその塩を、０．４〜２．５（Ｗ／Ｗ）％含有させることが記載されている。
このように、測定値誤差の軽減を図るために、反応性物質結合微小粒子の沈降することを抑制し、試薬または反応液中での濃度を長期間、均一に保持する技術が望まれている。特に、自動分析装置においては、試薬をセットした後、攪拌操作を怠たると測定誤差が生じ、臨床判断ミスに繋がりかねないことから、反応性物質結合微小粒子の溶液中での沈降抑制方法、それを用いた測定試薬の開発は重要と考えられる。 Thus, in order to reduce the measurement value error, there is a demand for a technique for suppressing the precipitation of the reactive substance-bound microparticles and maintaining the concentration in the reagent or the reaction solution uniformly for a long period of time. . In particular, in an automatic analyzer, if a stirring operation is neglected after setting a reagent, a measurement error occurs, which may lead to a clinical judgment error. Therefore, a method for suppressing sedimentation of reactive substance-bound microparticles in a solution, The development of measurement reagents using sac is considered important.
したがって、本発明の目的は、反応性物質結合微小粒子の分散液中での該微小粒子の沈降を抑制する方法を提供することである。本発明の目的はまた、静置保存後または自動免疫分析装置にセット後、再度、攪拌操作にて分散させる必要がない、測定誤差の少ない試薬を提供することである。 Accordingly, an object of the present invention is to provide a method for suppressing sedimentation of microparticles in a dispersion of reactive substance-bound microparticles. Another object of the present invention is to provide a reagent with little measurement error that does not need to be dispersed again by stirring after storage at rest or after setting in an automatic immunoanalyzer.
本発明者らは、上記課題を達成するために鋭意検討した結果、反応性物質結合微小粒子の分散液中において、ポリアニオンおよびその塩、デキストラン、シクロデキストリン、ポリエチレングリコール、およびグリセロールからなる群より選択される少なくとも１種の化合物を共存させることにより、反応性物質結合微小粒子の沈降を抑制し、かつ分散液中の反応性物質結合微小粒子の濃度を長期にわたり均一に保持できることを見出して、本発明を完成するに至った。 As a result of intensive studies to achieve the above-mentioned problems, the present inventors have selected from the group consisting of a polyanion and a salt thereof, dextran, cyclodextrin, polyethylene glycol, and glycerol in a dispersion of reactive substance-bound microparticles. By coexisting at least one kind of compound, it was found that the sedimentation of the reactive substance-bound microparticles can be suppressed and the concentration of the reactive substance-bound microparticles in the dispersion can be maintained uniformly over a long period of time. The invention has been completed.
本発明は、反応性を有する物質が結合した微小粒子の沈降抑制方法を提供し、該方法は、該微小粒子の分散液中に、ポリアニオンおよびその塩、デキストラン、シクロデキストリン、ポリエチレングリコール、およびグリセロールからなる群より選択される少なくとも１種を共存させる工程を含む。 The present invention provides a method for suppressing sedimentation of microparticles to which a substance having reactivity is bound, wherein the method includes a polyanion and a salt thereof, dextran, cyclodextrin, polyethylene glycol, and glycerol in a dispersion of the microparticles. A step of coexisting at least one selected from the group consisting of:
１つの実施態様においては、上記分散液中に、上記ポリアニオンおよびその塩は０．３〜５質量％、上記デキストランは０．１〜５質量％、上記シクロデキストリンは０．１〜５質量％、上記ポリエチレングリコールは０．３〜５質量％、または前記グリセロールは５〜４０質量％の割合で含有される。 In one embodiment, in the dispersion, the polyanion and a salt thereof are 0.3 to 5% by mass, the dextran is 0.1 to 5% by mass, the cyclodextrin is 0.1 to 5% by mass, The polyethylene glycol is contained in an amount of 0.3 to 5% by mass, or the glycerol is contained in an amount of 5 to 40% by mass.
他の実施態様においては、上記ポリアニオンまたはその塩は、硫酸基を有する水溶性高分子化合物である。 In another embodiment, the polyanion or a salt thereof is a water-soluble polymer compound having a sulfate group.
別の実施態様においては、上記ポリアニオンは、デキストラン硫酸またはヘパリンである。 In another embodiment, the polyanion is dextran sulfate or heparin.
別の実施態様においては、上記反応性を有する物質が結合した微小粒子は、抗体または抗原が結合した金コロイド粒子である。 In another embodiment, the microparticle to which the reactive substance is bound is a colloidal gold particle to which an antibody or an antigen is bound.
本発明の試薬は、反応性を有する物質が結合した微小粒子と、ポリアニオンおよびその塩、デキストラン、シクロデキストリン、ポリエチレングリコール、およびグリセロールからなる群より選択される少なくとも１種の化合物とを含み、該微小粒子の沈降が抑制されている。 The reagent of the present invention comprises microparticles bound with a reactive substance, and at least one compound selected from the group consisting of polyanions and salts thereof, dextran, cyclodextrin, polyethylene glycol, and glycerol, Sedimentation of fine particles is suppressed.
１つの実施態様においては、上記試薬中に、上記ポリアニオンおよびその塩は０．３〜５質量％、上記デキストランは０．３〜５質量％、上記シクロデキストリンは０．１〜５質量％、上記ポリエチレングリコールは０．５〜５質量％、または上記グリセロールは５〜４０質量％の割合で含有される。 In one embodiment, the polyanion and a salt thereof are 0.3 to 5% by mass, the dextran is 0.3 to 5% by mass, the cyclodextrin is 0.1 to 5% by mass, and the reagent is contained in the reagent. Polyethylene glycol is contained in a proportion of 0.5 to 5% by mass, or the glycerol is contained in a proportion of 5 to 40% by mass.
他の実施態様においては、上記ポリアニオンまたはその塩は、硫酸基を有する水溶性高分子化合物である。 In another embodiment, the polyanion or a salt thereof is a water-soluble polymer compound having a sulfate group.
別の実施態様においては、上記ポリアニオンは、デキストラン硫酸またはヘパリンである。 In another embodiment, the polyanion is dextran sulfate or heparin.
別の実施態様においては、上記反応性を有する物質が結合した微小粒子は、抗体または抗原が結合した金コロイド粒子である。 In another embodiment, the microparticle to which the reactive substance is bound is a colloidal gold particle to which an antibody or an antigen is bound.
本発明の試薬キットは、上記試薬を含む。 The reagent kit of the present invention includes the reagent.
本発明の自動化免疫測定方法は、上記試薬と、試料とを混合する工程を含む。 The automated immunoassay method of the present invention includes a step of mixing the reagent and the sample.
本発明によれば、反応性物質結合微小粒子の沈降を抑制することができる。したがって、該微小粒子の沈降が抑制された試薬の提供が可能となる。この試薬は、該微小粒子の濃度が長期にわたり均一に保持されるため、例えば、この試薬を用いて免疫測定を行う場合には、該試薬を測定毎に攪拌せずとも、反応性物質結合微小粒子が最終反応液に等量分注することができるため、誤差の少ない安定した測定値を得ることが可能となる。 According to the present invention, sedimentation of reactive substance-bound microparticles can be suppressed. Therefore, it is possible to provide a reagent in which sedimentation of the fine particles is suppressed. Since this reagent maintains a uniform concentration of the microparticles over a long period of time, for example, when immunoassay is performed using this reagent, the reactive substance-bound microparticles can be obtained without stirring the reagent for each measurement. Since particles can be equally dispensed into the final reaction solution, it is possible to obtain a stable measurement value with little error.
具体的には、反応性物質結合微小粒子含有試薬を自動分析装置にセットして長期間連続して測定する場合、あるいは一定期間をおいて測定する場合、従来必要であった、測定毎または一定期間毎の該微小粒子含有試薬を攪拌して、分散液中の濃度を均一にする操作を必要とせず、長期にわたり誤差の少ない正確な測定値を得ることができる。 Specifically, when a reagent containing reactive substance-bound microparticles is set in an automatic analyzer and measured continuously for a long period of time, or when measured after a certain period of time, it has been necessary for each measurement or constant. It is not necessary to stir the fine particle-containing reagent for each period to make the concentration in the dispersion uniform, and it is possible to obtain an accurate measurement value with little error over a long period of time.
これにより、測定者にとって大変な負担となっていた、煩雑な攪拌操作の必要性を無くすとともに、攪拌操作を怠ったことから生じる測定誤差およびそれによる臨床判断ミスを防ぐことができる。 As a result, it is possible to eliminate the need for a complicated stirring operation, which has been a heavy burden on the measurer, and to prevent measurement errors and clinical judgment errors resulting from the failure of the stirring operation.
１．反応性物質結合微小粒子の沈降抑制方法
本発明の反応性物質結合微小粒子の沈降抑制方法は、該微小粒子の分散液中に、ポリアニオンおよびその塩、デキストラン、シクロデキストリン、ポリエチレングリコール、およびグリセロールからなる群より選択される少なくとも１種を共存させる工程を含む。
1. Method for inhibiting sedimentation of reactive substance-bound microparticles In the method for inhibiting sedimentation of reactive substance-bound microparticles of the present invention, a dispersion of the microparticles comprises a polyanion and a salt thereof, dextran, cyclodextrin, polyethylene glycol, and glycerol. A step of coexisting at least one selected from the group consisting of:
本発明の方法に用いられる反応性物質結合微小粒子は、免疫測定試薬として使用され得る微小粒子であり、好ましくはラテックス粒子および金属コロイド粒子である。金属コロイド粒子としては、金コロイド粒子が一般的に利用され易く、好ましく用いられる。金コロイド粒子は、市販品を用いてもよいし、当業者が通常用いる方法、例えば塩化金酸をクエン酸ナトリウムで還元する方法により調製してもよい。金コロイド粒子の粒径は、通常５ｎｍ〜１００ｎｍ、好ましくは３０ｎｍ〜６０ｎｍの範囲である。 The reactive substance-bound microparticles used in the method of the present invention are microparticles that can be used as an immunoassay reagent, and are preferably latex particles and metal colloid particles. As the metal colloid particles, gold colloid particles are generally easily used and preferably used. Commercially available gold colloidal particles may be used, or may be prepared by a method commonly used by those skilled in the art, for example, a method of reducing chloroauric acid with sodium citrate. The particle size of the gold colloidal particles is usually in the range of 5 nm to 100 nm, preferably 30 nm to 60 nm.
上記微小粒子に結合させる物質については、測定対象物質に特異的に結合するものであれば利用可能である。例えば、抗体、抗原、レセプター、レクチン、デオキシリボ核酸（ＤＮＡ）、リボ核酸（ＲＮＡ）などの結合親和性を有する物質が挙げられる。 Any substance that binds to the fine particles can be used as long as it binds specifically to the substance to be measured. Examples include substances having binding affinity such as antibodies, antigens, receptors, lectins, deoxyribonucleic acid (DNA), and ribonucleic acid (RNA).
本発明の方法においては、ポリアニオンおよびその塩、デキストラン、シクロデキストリン、ポリエチレングリコール、またはグリセロールが用いられる。本明細書においては、これらの化合物を沈降抑制物質という。沈降抑制物質は、単独で用いてもよく、２以上を組み合わせて用いてもよい。 In the method of the present invention, a polyanion and a salt thereof, dextran, cyclodextrin, polyethylene glycol, or glycerol is used. In the present specification, these compounds are referred to as sedimentation inhibitors. A sedimentation-inhibiting substance may be used alone or in combination of two or more.
上記沈降抑制物質の１種であるポリアニオンとしては、例えば、デキストラン硫酸、へパリン、ポリスチレンスルホン酸、ヒアルロン酸、およびコンドロイチン硫酸が挙げられる。ポリアニオンの塩としては、例えば、デキストラン硫酸ナトリウム、ヘパリンナトリウムなどが挙げられる。ポリアニオンまたはその塩の中でも、沈降抑制効果が高い観点から、硫酸基を有する水溶性高分子化合物が好適に用いられる。このような化合物は、例えば、デキストラン硫酸、ヘパリン、デキストラン硫酸ナトリウム、およびヘパリンナトリウムである。 Examples of the polyanion that is one kind of the precipitation-inhibiting substance include dextran sulfate, heparin, polystyrene sulfonate, hyaluronic acid, and chondroitin sulfate. Examples of the polyanion salt include dextran sodium sulfate and heparin sodium. Among polyanions or salts thereof, a water-soluble polymer compound having a sulfate group is preferably used from the viewpoint of a high sedimentation suppressing effect. Such compounds are, for example, dextran sulfate, heparin, dextran sulfate sodium, and heparin sodium.
本発明の方法は、上記反応性物質結合微小粒子の分散液中に、上記沈降抑制物質を共存させる。共存させる手段は、特に制限されない。例えば、反応性物質結合微小粒子の分散液に沈降抑制物質を加えてもよいし、沈降抑制物質または沈降抑制物質を分散媒で希釈した希釈液に、反応性物質結合微小粒子を加えてもよいし、あるいは反応性物質結合微小粒子と沈降抑制物質とを混合し、この混合物を分散媒に加えてもよい。なお、分散媒は、特に制限されないが、例えば、水、あるいは後述する緩衝剤を用いた緩衝液などが用いられる。 In the method of the present invention, the precipitation-inhibiting substance is allowed to coexist in the dispersion of the reactive substance-bound microparticles. The means for coexisting is not particularly limited. For example, the sedimentation-inhibiting substance may be added to the dispersion of reactive substance-bound microparticles, or the reactive substance-bound microparticles may be added to a dilution liquid in which the sedimentation-inhibiting substance or the sedimentation-inhibiting substance is diluted with a dispersion medium. Alternatively, the reactive substance-bound microparticles and the sedimentation-inhibiting substance may be mixed and this mixture added to the dispersion medium. The dispersion medium is not particularly limited, and for example, water or a buffer solution using a buffer agent described later is used.
本発明の方法において、分散液中の反応性物質結合微小粒子の濃度は、当該分野で通常採用される濃度であり得る。 In the method of the present invention, the concentration of the reactive substance-bound microparticles in the dispersion can be a concentration that is usually employed in the art.
本発明の方法において、分散液中に共存される沈降抑制物質の濃度は、沈降抑制物質の種類に応じて適宜設定される。例えば、ポリアニオンまたはその塩の場合、好ましくは０．３〜５質量％、より好ましくは０．５〜２質量％、さらに好ましくは０．７〜１．１質量％である。デキストランまたはシクロデキストリンの場合、好ましくは０．１〜５質量％、より好ましくは０．２〜１．８質量％、さらに好ましくは０．５〜１．５質量％である。ポリエチレングリコールの場合、好ましくは０．３〜５質量％、より好ましくは０．５〜３質量％である。グリセロールの場合、好ましくは５〜４０質量％、より好ましくは１０〜３５質量％である。 In the method of the present invention, the concentration of the sedimentation-inhibiting substance coexisting in the dispersion is appropriately set according to the type of the sedimentation-inhibiting substance. For example, in the case of a polyanion or a salt thereof, it is preferably 0.3 to 5% by mass, more preferably 0.5 to 2% by mass, and still more preferably 0.7 to 1.1% by mass. In the case of dextran or cyclodextrin, it is preferably 0.1 to 5% by mass, more preferably 0.2 to 1.8% by mass, and still more preferably 0.5 to 1.5% by mass. In the case of polyethylene glycol, it is preferably 0.3 to 5% by mass, more preferably 0.5 to 3% by mass. In the case of glycerol, it is preferably 5 to 40% by mass, more preferably 10 to 35% by mass.
本発明の方法によれば、反応性物質結合微小粒子の分散液中に、沈降抑制物質を共存させることによって、反応性物質結合微小粒子の沈降を抑制することができる。したがって、この方法を用いることによって、分散液中で該微小粒子を長期にわたり均一に保持することが可能となる。 According to the method of the present invention, the precipitation of the reactive substance-bound microparticles can be suppressed by allowing the precipitation-inhibiting substance to coexist in the dispersion liquid of the reactive substance-bound microparticles. Therefore, by using this method, the fine particles can be uniformly held for a long time in the dispersion.
２．反応性物質結合微小粒子と沈降抑制物質とを含む試薬
本発明の試薬は、上記反応性物質結合微小粒子と、上記沈降抑制物質とを含み、必要に応じて、緩衝剤、糖、糖アルコール、アルブミン、塩化ナトリウム、防腐剤、およびその他の添加剤を含む。この試薬は、反応性物質結合微小粒子の沈降が抑制されているため、該微小粒子の濃度が長期にわたり均一に保持される。本発明の試薬は、通常、液状であり、反応性物質結合微小粒子を用いた試薬、特に当該分野で通常用いられる免疫測定用試薬の第二試薬として用いられる。
2. Reagent containing reactive substance-bound microparticles and sedimentation-inhibiting substance The reagent of the present invention comprises the reactive substance-bound microparticles and the sedimentation-inhibiting substance, and if necessary, a buffer, sugar, sugar alcohol, Contains albumin, sodium chloride, preservatives, and other additives. Since this reagent suppresses sedimentation of the reactive substance-bound microparticles, the concentration of the microparticles is uniformly maintained over a long period of time. The reagent of the present invention is usually liquid and used as a second reagent of a reagent using reactive substance-bound microparticles, particularly an immunoassay reagent usually used in this field.
本発明の試薬中の反応性物質結合微小粒子の濃度、および沈降抑制物質の濃度は、特に制限されない。反応性物質結合微小粒子の沈降の抑制を高める観点から、上記方法で採用される濃度の範囲内であることが好ましい。 The concentration of the reactive substance-bound microparticles and the concentration of the precipitation-inhibiting substance in the reagent of the present invention are not particularly limited. From the viewpoint of increasing the suppression of sedimentation of the reactive substance-bound microparticles, it is preferably within the range of the concentration employed in the above method.
本発明の試薬に含有され得る緩衝剤としては、リン酸緩衝液；トリス塩酸緩衝液；コハク酸緩衝液；グリシルグリシン、ＭＥＳ（２−（Ｎ−モルホリノ）エタンスルホン酸）、ＨＥＰＥＳ（Ｎ−２−ヒドロキシエチル−ピペラジン−Ｎ’−エタンスルホン酸）、ＴＥＳ（Ｎ−トリス（ヒドロキシメチル）メチル−２−アミノエタンスルホン酸）、ＭＯＰＳ（３−（Ｎ−モルホリノ）プロパンスルホン酸）、ＰＩＰＥＳ（ピペラジン−１，４−ビス（２−エタンスルホン酸））、Ｂｉｓ−Ｔｒｉｓ（ビス（２−ヒドロキシエチル）イミノトリス（ヒドロキシメチル）メタン）などのグッド緩衝液などが挙げられる。上記緩衝剤は、試薬中のｐＨが５〜９、あるいは濃度が１〜１００ｍＭとなるように含有されることが好ましい。 The buffering agent may be contained in the reagent of the present invention, a phosphate buffer; Tris-HCl gentle shock solution; succinate buffer; glycylglycine, MES (2- (N- molar Horino) ethanesulfonic acid), HEPES (N-2-hydroxyethyl-piperazine-N′-ethanesulfonic acid), TES (N-tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid), MOPS (3- (N-morpholino) propanesulfonic acid) Good buffers such as PIPES (piperazine-1,4-bis (2-ethanesulfonic acid)) and Bis-Tris (bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane). The buffer is preferably contained so that the pH in the reagent is 5 to 9 or the concentration is 1 to 100 mM.
本発明の試薬に含有され得る糖および糖アルコールとしては、グルコース、マンノース、サッカロース、ラクトース、マルトース、マンニトール、ソルビトールなどが挙げられる。上記糖または糖アルコールは、試薬中の濃度が０．０１〜１０質量％であることが好ましい。 Examples of the sugar and sugar alcohol that can be contained in the reagent of the present invention include glucose, mannose, saccharose, lactose, maltose, mannitol, sorbitol and the like. The sugar or sugar alcohol preferably has a concentration in the reagent of 0.01 to 10% by mass.
本発明の試薬に含有され得るアルブミンとしては、ウシ血清アルブミン（ＢＳＡ）などが挙げられる。アルブミンは、試薬中の濃度が０．００１〜１質量％であることが好ましい。 Examples of albumin that can be contained in the reagent of the present invention include bovine serum albumin (BSA). It is preferable that the concentration of albumin in the reagent is 0.001 to 1% by mass.
本発明の試薬に含有され得る防腐剤としては、アジ化ナトリウムなどが挙げられる。防腐剤は、試薬中の濃度が０.０１〜０．５質量％であることが好ましい。 Examples of the preservative that can be contained in the reagent of the present invention include sodium azide. The preservative preferably has a concentration in the reagent of 0.01 to 0.5% by mass.
本発明の試薬に含有され得るその他の添加剤としては、ツィーン２０、ポリエチレングリコールラウリルエーテル、５−ブロモサリチル酸、サリチル酸ナトリウム、安息香酸ナトリウム、ベンゼンスルホン酸ナトリウム、フェノール、チモールなどが挙げられる。 Other additives that may be included in the reagent of the present invention include Tween 20, polyethylene glycol lauryl ether, 5-bromosalicylic acid, sodium salicylate, sodium benzoate, sodium benzenesulfonate, phenol, thymol, and the like.
本発明の試薬は、上記のように、反応性物質結合微小粒子の沈降が抑制されているため、該微小粒子の濃度が長期にわたり均一に保持される。したがって、例えば、この試薬を用いて免疫測定を行う場合には、測定毎に該試薬を攪拌せずとも、反応性物質結合微小粒子を最終反応液に等量分注することができ、誤差の少ない安定した測定値を得ることが可能となる。 As described above, the reagent of the present invention suppresses sedimentation of the reactive substance-bound microparticles, so that the concentration of the microparticles is uniformly maintained over a long period of time. Therefore, for example, when immunoassay is performed using this reagent, it is possible to dispense an equal amount of reactive substance-bound microparticles into the final reaction solution without stirring the reagent for each measurement. A small number of stable measurement values can be obtained.
３．試薬キット
本発明の試薬キットは、上記反応性物質結合微小粒子と沈降抑制物質とを含む試薬（本発明の試薬）を含む。この試薬キットは、例えば、ラテックス凝集法、金コロイド凝集法などを用いた免疫測定、特に自動化免疫測定に用いられる。
3. Reagent kit The reagent kit of the present invention includes a reagent (the reagent of the present invention) containing the reactive substance-bound microparticles and the precipitation-inhibiting substance. This reagent kit is used for immunoassay using, for example, latex agglutination method, colloidal gold agglutination method, etc., particularly for automated immunoassay.
本発明の試薬キットが免疫測定用試薬キットとして用いられる場合、そのキットは、通常、試料の希釈、試料の免疫反応前の前処理、および免疫反応を補助する成分などを含有する第一試薬、本発明の試薬（第二試薬）、および必要に応じて、検量線作成用の測定対象物質の標準品から構成され得る。 When the reagent kit of the present invention is used as a reagent kit for immunoassay, the kit is usually a first reagent containing sample dilution, pretreatment before immune reaction of the sample, components for assisting immune reaction, etc. The reagent (second reagent) of the present invention and, if necessary, a standard product of a measurement target substance for preparing a calibration curve may be used.
本発明の試薬キットは、本発明の試薬中の微小粒子に結合された反応性物質に応じて、試料中の種々の物質を測定対象とすることができる。測定対象となり得る物質（測定対象物質）としては、例えば、アルブミン、ヘモグロビン、ヘモグロビンＡ１ｃ、ミオグロビン、トランスフェリン、ラクトフェリン、シスタチンＣ、フェリチン、α−フェトプロテイン、癌胎児性抗原、ＣＡ１９−９、前立腺特異抗原、Ｃ反応性蛋白質（ＣＲＰ）、繊維素分解産物（ＦＤＰ）、ペプシノーゲンＩおよびＩＩ、コラーゲンなどの蛋白質；高比重リポ蛋白質、低比重リポ蛋白質、超低比重リポ蛋白質などの脂質蛋白質；デオキシリボ核酸、リボ核酸などの核酸；アルカリ性ホスファターゼ、乳酸脱水素酵素、リパーゼ、アミラーゼなどの酵素；ＩｇＧ、ＩｇＭ、ＩｇＡ、ＩｇＤ、ＩｇＥなどの免疫グロブリン；Ｂ型肝炎ウイルス、Ｃ型肝炎ウイルス、ヒト免疫不全ウイルス、ヘリコバクターピロリ、およびこれらに対する抗体などの感染症に関する抗原や抗体；ハロペリドール、ブロムペリドールなどの薬物；性ホルモンなどのホルモンなどが挙げられる。 The reagent kit of the present invention can measure various substances in a sample depending on the reactive substance bound to the microparticles in the reagent of the present invention. Examples of substances that can be measured (measuring substances) include albumin, hemoglobin, hemoglobin A1c, myoglobin, transferrin, lactoferrin, cystatin C, ferritin, α-fetoprotein, carcinoembryonic antigen, CA19-9, prostate specific antigen, Proteins such as C-reactive protein (CRP), fibrinolysis products (FDP), pepsinogens I and II, and collagen; lipid proteins such as high-density lipoprotein, low-density lipoprotein, and ultra-low density lipoprotein; deoxyribonucleic acid, ribo Nucleic acids such as nucleic acids; enzymes such as alkaline phosphatase, lactate dehydrogenase, lipase, amylase; immunoglobulins such as IgG, IgM, IgA, IgD, IgE; hepatitis B virus, hepatitis C virus, human immunodeficiency virus, Helicobacter Piro , And antigen and antibodies for infectious diseases, such as antibodies to these; haloperidol, drugs such as bromperidol; and hormones such as sex hormones and the like.
測定に供する測定対象物質を含む試料としては、血液、血漿、血清、尿、糞便（懸濁液）、髄液、腹水などの生体試料、環境中より得られたサンプルまたはその抽出物などが挙げられる。 Examples of the sample containing the substance to be measured to be used include biological samples such as blood, plasma, serum, urine, stool (suspension), cerebrospinal fluid, ascites, samples obtained from the environment, or extracts thereof. It is done.
４．自動化免疫測定方法
本発明の自動化免疫測定方法は、本発明の試薬を用いて行われる。この自動化免疫測定方法は、試薬中において、反応性物質結合微小粒子の沈降が抑制され、その濃度が長期にわたり均一に保持されるため、測定毎に該試薬を攪拌せずとも、反応性物質結合微小粒子を最終反応液に等量分注することができ、誤差の少ない安定した測定値を得ることができる。
4). Automated immunoassay method The automated immunoassay method of the present invention is carried out using the reagent of the present invention. In this automated immunoassay method, the precipitation of reactive substance-bound microparticles is suppressed in the reagent, and the concentration is kept uniform over a long period of time. An equal amount of fine particles can be dispensed into the final reaction solution, and a stable measurement value with few errors can be obtained.
本発明の自動化免疫測定方法は、具体的には、試料、第一試薬、および本発明の試薬（第二試薬）を自動分析装置にセットし、試料に、第一試薬および第二試薬を順次自動的に混合することによって行われる。第一試薬と第二試薬との割合は、適宜設定される。好ましくは本発明の試薬（第二試薬）は、２〜９倍、より好ましくは３〜５倍に希釈される。 Specifically, in the automated immunoassay method of the present invention, the sample, the first reagent, and the reagent (second reagent) of the present invention are set in an automatic analyzer, and the first reagent and the second reagent are sequentially added to the sample. This is done by automatically mixing. The ratio between the first reagent and the second reagent is set as appropriate. Preferably, the reagent of the present invention (second reagent) is diluted 2 to 9 times, more preferably 3 to 5 times.
本発明の自動化免疫測定方法は、例えば、長期間連続して測定する場合、あるいは、一定期間をおいて測定する場合であっても、従来必要であった、測定毎または一定期間毎の該微小粒子含有試薬を攪拌して、溶液中の濃度を均一にする操作を必要とせず、長期にわたり誤差の少ない正確な測定値を得ることができる。 The automated immunoassay method of the present invention is, for example, a method that is necessary in the past even when measuring continuously for a long period of time, or when measuring at a fixed period, for every minute or every fixed period. It is not necessary to stir the particle-containing reagent to make the concentration in the solution uniform, and it is possible to obtain an accurate measurement value with little error over a long period of time.
以下、実施例に基づいて本発明をさらに具体的に説明するが、本発明はこれらによって限定されるものではない。以下の実施例において、特に記載がない限り、％はいずれも質量／容量％（Ｗ／Ｖ％）を表す。 EXAMPLES Hereinafter, although this invention is demonstrated further more concretely based on an Example, this invention is not limited by these. In the following examples, unless otherwise specified,% represents mass / volume% (W / V%).
実施例１：金コロイド液の調製
９５℃の蒸留水１Ｌに１０％塩化金酸溶液２ｍＬを攪拌しながら加え、１分後に２％クエン酸ナトリウム溶液１０ｍＬを加え、さらに２０分間攪拌した後、３０℃に冷却した。冷却後、０．１％炭酸カリウムでｐＨ７．１に調節した。
Example 1: Preparation of
実施例２：シスタチンＣ測定用第一試薬の調製
５％塩化ナトリウム、０．２％ＥＤＴＡ、０．２％アルキルフェニルジスルホン酸ナトリウム塩、および０．３５％ポリオキシエチレンラウリルエーテルを含む０．５Ｍ Ｂｉｓ−Ｔｒｉｓ（ｐＨ６．７）溶液に、反応促進剤としてポリエチレングリコールを１．０〜２．５％程度添加してシスタチンＣ測定用第一試薬とした。
Example 2 Preparation of First Reagent for Cystatin C Measurement 0.5 M containing 5% sodium chloride, 0.2% EDTA, 0.2% alkylphenyl disulfonic acid sodium salt, and 0.35% polyoxyethylene lauryl ether About 1.0 to 2.5% of polyethylene glycol as a reaction accelerator was added to a Bis-Tris (pH 6.7) solution to obtain a first reagent for cystatin C measurement.
実施例３：抗シスタチンＣ抗体結合金コロイド試薬（第二試薬）の調製
抗シスタチンＣ抗体（ダコ・ジャパン株式会社）を、０．０５％アジ化ナトリウムを含む１０ｍＭ ＨＥＰＥＳ（ｐＨ７．１）で希釈し、５０μｇ／ｍＬの濃度にした。この抗シスタチンＣ抗体溶液１００ｍＬを、実施例１で調製した金コロイド液約１Ｌに加え、冷蔵下で２時間攪拌した。さらに、５．４６％マンニトール、０．５％ＢＳＡ、および０．０５％アジ化ナトリウムを含む１０ｍＭ ＨＥＰＥＳ（ｐＨ７．１）を１１０ｍＬ添加し、３７℃で９０分間攪拌した。次いで、８０００回転で４０分間遠心分離し、上清を除去した後、３％マンニトール、０．１％ＢＳＡ、および０．０５％アジ化ナトリウムを含む５ｍＭ ＨＥＰＥＳ（ｐＨ７．５）（Ａ溶液）を約１Ｌ加え、抗体結合金コロイドを分散させた。さらに、８０００回転で４０分間遠心分離し、上清を除去し、Ａ溶液で抗体感作金コロイドを分散させ、全量を２１０ｍＬとし、抗シスタチンＣ抗体結合金コロイド試薬（第二試薬）を得た。
Example 3: Preparation of anti-cystatin C antibody-binding gold colloid reagent (second reagent) Anti-cystatin C antibody (Dako Japan Co., Ltd.) was diluted with 10 mM HEPES (pH 7.1) containing 0.05% sodium azide. To a concentration of 50 μg / mL. 100 mL of this anti-cystatin C antibody solution was added to about 1 L of the colloidal gold solution prepared in Example 1, and stirred for 2 hours under refrigeration. Further, 110 mL of 10 mM HEPES (pH 7.1) containing 5.46% mannitol, 0.5% BSA, and 0.05% sodium azide was added, and the mixture was stirred at 37 ° C. for 90 minutes. Next, after centrifuging at 8000 rpm for 40 minutes and removing the supernatant, 5 mM HEPES (pH 7.5) (solution A) containing 3% mannitol, 0.1% BSA, and 0.05% sodium azide was added. About 1 L was added to disperse the antibody-bound gold colloid. Further, the mixture was centrifuged at 8000 rpm for 40 minutes, the supernatant was removed, and the antibody-sensitized gold colloid was dispersed with the solution A to make the total volume 210 mL to obtain an anti-cystatin C antibody-binding gold colloid reagent (second reagent). .
実施例４：グリセロールまたはポリエチレングリコールの添加効果の検討
（１）シスタチンＣ濃度が約８ｍｇ／Ｌの試料（試料１）の測定
抗シスタチンＣ抗体結合金コロイド試薬（第二試薬）に、グリセロールを３３％含有するように添加して、グリセロール含有第二試薬を調製した。
Example 4: Examination of Addition Effect of Glycerol or Polyethylene Glycol (1) Measurement of Sample (Sample 1) with Cystatin C Concentration of about 8 mg / L Glycerol was added to the anti-cystatin C antibody-conjugated gold colloid reagent (second reagent). A glycerol-containing second reagent was prepared by adding the glycerol.
日立７０７０自動分析装置に、シスタチンＣ濃度が約８ｍｇ／Ｌの試料（試料１）、実施例２で調製した第一試薬、および上記グリセロール含有第二試薬をそれぞれセットして、以下の条件下でセット時の吸光度変化量を測定した。 In the Hitachi 7070 automatic analyzer, a sample (sample 1) having a cystatin C concentration of about 8 mg / L, the first reagent prepared in Example 2 and the second glycerol-containing second reagent were set. The amount of change in absorbance at the time of setting was measured.
（測定条件）
３μＬの試料１に、第一試薬を２４０μＬ分注し、３７℃で約５分間加温し、次いで、グリセロール含有第二試薬を６０μＬ分注し、３７℃で反応した。その後、主波長５４６ｎｍおよび副波長６６０ｎｍで測光ポイント１８から３１の二ポイント測定を行って、二ポイント間の吸光度変化量を測定した。なお、吸光度変化量は、上記第二試薬を分注する際に、攪拌しなかった場合（無攪拌吸光度変化量）および予め攪拌した場合（攪拌吸光度変化量）のそれぞれについて測定した。
(Measurement condition)
To 3 μL of sample 1, 240 μL of the first reagent was dispensed and heated at 37 ° C. for about 5 minutes, and then 60 μL of the second reagent containing glycerol was dispensed and reacted at 37 ° C. Thereafter, two-point measurement was performed from photometry points 18 to 31 at a main wavelength of 546 nm and a sub-wavelength of 660 nm, and the change in absorbance between the two points was measured. The amount of change in absorbance was measured for each of the cases where the second reagent was dispensed without stirring (unstirred absorbance variation) and when pre-stirred (stirring absorbance variation).
測定後、１日経過した後、上記と同様にして、１日経過後の吸光度変化量（無攪拌吸光度変化量および攪拌吸光度変化量）を測定した。 One day after the measurement, the change in absorbance after one day (the amount of change without stirring and the amount of change in stirring absorbance) was measured in the same manner as described above.
得られたセット時および１日経過後の無攪拌吸光度変化量と、攪拌吸光度変化量とからそれぞれの測定値差を算出した。結果を表１に示す。 The difference between the measured values was calculated from the amount of change in absorbance without stirring and the amount of change in absorbance after stirring for 1 day after setting. The results are shown in Table 1.
他方、グリセロール含有第二試薬の代わりに、ポリエチレングリコール（ＰＥＧ）を２％含有する第二試薬（ＰＥＧ含有第二試薬）、グリセロールを３３％およびＰＥＧを２％含有する第二試薬（混合物含有第二試薬）、または第二試薬をそのまま用いたこと以外は、上記と同様にして、吸光度変化量を測定し、測定値差を算出した。結果を表１に併せて示す。 On the other hand, instead of the second reagent containing glycerol, a second reagent containing 2% polyethylene glycol (PEG) (second reagent containing PEG), a second reagent containing 33% glycerol and 2% PEG (mixture-containing second reagent). The amount of change in absorbance was measured in the same manner as described above except that the second reagent) or the second reagent was used as it was, and the difference between the measured values was calculated. The results are also shown in Table 1.
（２）シスタチンＣ濃度が約４ｍｇ／Ｌの試料（試料２）の測定
試料１の代わりに、シスタチンＣ濃度が約４ｍｇ／Ｌの試料（試料２）を用いたこと以外は、上記（１）と同様にして、測定値差を算出した。結果を表２に示す。
(2) Measurement of a sample (sample 2) having a cystatin C concentration of about 4 mg / L The above (1) except that a sample (sample 2) having a cystatin C concentration of about 4 mg / L was used instead of the sample 1 In the same manner as described above, the measured value difference was calculated. The results are shown in Table 2.
（３）シスタチンＣ濃度が約１ｍｇ／Ｌの試料（試料３）の測定
試料１の代わりに、シスタチンＣ濃度が約１ｍｇ／Ｌの試料（試料３）を用いたこと以外は、上記（１）と同様にして、測定値差を算出した。結果を表３に示す。
(3) Measurement of a sample (sample 3) having a cystatin C concentration of about 1 mg / L The above (1) except that a sample (sample 3) having a cystatin C concentration of about 1 mg / L was used instead of the sample 1 In the same manner as described above, the measured value difference was calculated. The results are shown in Table 3.
上記表１〜３の結果から明らかなように、第二試薬に沈降抑制物質（グリセロール、ポリエチレングリコール、またはグリセロールとポリエチレングリコールとの混合物）を加えた場合は、沈降抑制物質を加えない場合に比べて、１日経過後の測定値差が格段に小さかった。沈降抑制物質を加えない場合は、１日経過すると、抗体結合金コロイド粒子が重力により沈降するため、試薬液上層部の濃度が希薄になる。したがって、測定直前に攪拌しなければ、自動分析装置では濃度の希薄になった上層域から試薬を反応セルへ分注されるために、反応に直接関与する抗体結合金コロイド粒子量が減少し、吸光度変化量が大幅に減少する。このため、１日静置後では、測定前に抗体結合金コロイド試薬を攪拌した場合と攪拌しなかった場合の吸光度変化量を比較すると同一試料を測定しているにもかかわらず、大きな差が認められた。 As is clear from the results in Tables 1 to 3 above, when the precipitation inhibitor (glycerol, polyethylene glycol, or a mixture of glycerol and polyethylene glycol) was added to the second reagent, compared to the case where no precipitation inhibitor was added. The difference in measured values after the passage of one day was much smaller. When no precipitation inhibitor is added, the concentration of the upper layer of the reagent solution becomes dilute because the antibody-bound gold colloidal particles settle due to gravity after one day. Therefore, if the stirring is not performed immediately before the measurement, the reagent is dispensed from the upper region where the concentration is diluted to the reaction cell in the automatic analyzer, so the amount of antibody-bound gold colloid particles directly involved in the reaction is reduced, The amount of change in absorbance is greatly reduced. For this reason, after standing for 1 day, comparing the amount of change in absorbance between when the antibody-bound gold colloid reagent is stirred and when it is not stirred before measurement, there is a large difference even though the same sample is measured. Admitted.
このことから、グリセロールおよび／またはポリエチレングリコールを抗体結合金コロイド試薬に添加することで、静置保存時に抗体結合金コロイド粒子の沈降が抑制され、抗体結合金コロイド試薬の均一性が保たれることがわかった。 Therefore, by adding glycerol and / or polyethylene glycol to the antibody-bound gold colloid reagent, the precipitation of antibody-bound gold colloid particles is suppressed during storage and the uniformity of the antibody-bound gold colloid reagent is maintained. I understood.
実施例５：デキストランまたはデキストラン硫酸ナトリウムの添加効果の検討
（１）シスタチンＣ濃度が約８ｍｇ／Ｌの試料（試料１）の測定
抗シスタチンＣ抗体結合金コロイド試薬（第二試薬）に、デキストランを１％含有するように添加して、デキストラン含有第二試薬を調製した。
Example 5: Examination of addition effect of dextran or dextran sulfate sodium (1) Measurement of sample (sample 1) having cystatin C concentration of about 8 mg / L Dextran was added to anti-cystatin C antibody-conjugated gold colloid reagent (second reagent). A second reagent containing dextran was prepared by adding 1%.
グリセロール含有第二試薬の代わりに、デキストラン含有第二試薬を用いたこと、およびセット時１日経過後の吸光度変化量の代わりに、セット時３日経過後の吸光度変化量を測定したこと以外は、実施例４の（１）と同様にして、吸光度変化量を測定し、測定値差を算出した。結果を表４に示す。 Implemented except that the second reagent containing dextran was used instead of the second reagent containing glycerol, and the change in absorbance after 3 days after setting was measured instead of the change in absorbance after 1 day after setting. In the same manner as in Example 4 (1), the change in absorbance was measured, and the difference in measured values was calculated. The results are shown in Table 4.
他方、デキストラン含有第二試薬の代わりに、デキストラン硫酸ナトリウムを１％含有する第二試薬（デキストラン硫酸含有第二試薬）または第二試薬をそのまま用いたこと以外は、上記と同様にして、吸光度変化量を測定し、測定値差を算出した。結果を表４に併せて示す。 On the other hand, in place of the dextran-containing second reagent, the absorbance change was performed in the same manner as above except that the second reagent containing 1% of dextran sulfate (second reagent containing dextran sulfate) or the second reagent was used as it was. The amount was measured and the difference between the measured values was calculated. The results are also shown in Table 4.
（２）シスタチンＣ濃度が約４ｍｇ／Ｌの試料（試料２）の測定
試料１の代わりに、シスタチンＣ濃度が約４ｍｇ／Ｌの試料（試料２）を用いたこと以外は、上記実施例５の（１）と同様にして、測定値差を算出した。結果を表５に示す。
(2) Measurement of sample (sample 2) having a cystatin C concentration of about 4 mg / L Example 5 was used except that a sample (sample 2) having a cystatin C concentration of about 4 mg / L was used instead of sample 1. The measured value difference was calculated in the same manner as (1). The results are shown in Table 5.
上記表４および５の結果から明らかなように、第二試薬に沈降抑制物質（デキストランまたはデキストラン硫酸ナトリウム）を加えた場合は、沈降抑制物質を加えない場合に比べて、３日経過後の測定値差が格段に小さかった。このことから、沈降抑制物質（デキストランまたはデキストラン硫酸ナトリウム）を抗体結合金コロイド試薬に添加することで、静置保存時に抗体結合金コロイド粒子の沈降が抑制され、抗体結合金コロイド試薬の均一性が保たれることがわかった。 As is apparent from the results of Tables 4 and 5 above, when a precipitation inhibitor (dextran or dextran sulfate sodium) was added to the second reagent, the measured value after 3 days was compared to when no precipitation inhibitor was added. The difference was much smaller. Therefore, by adding a sedimentation-inhibiting substance (dextran or dextran sulfate sodium salt) to the antibody-bound gold colloid reagent, the precipitation of antibody-bound gold colloid particles is suppressed during storage at rest, and the uniformity of the antibody-bound gold colloid reagent is improved. I understood that it was kept.
実施例６：へパリンナトリウムの添加効果の検討
（１）シスタチンＣ濃度が約８ｍｇ／Ｌの試料（試料１）の測定
抗シスタチンＣ抗体結合金コロイド試薬（第二液）に、ヘパリンナトリウムを１％含有するように添加して、ヘパリン含有第二試薬を調製した。
Example 6: Examination of addition effect of heparin sodium (1) Measurement of sample (sample 1) having cystatin C concentration of about 8 mg / L Heparin sodium was added to anti-cystatin C antibody-conjugated gold colloid reagent (second liquid). A heparin-containing second reagent was prepared by adding to contain a 2% content.
グリセロール含有第二試薬の代わりに、ヘパリン含有第二試薬を用いたこと、およびセット時１日経過後の吸光度変化量の代わりに、セット時２日経過後の吸光度変化量を測定したこと以外は、実施例４の（１）と同様にして、吸光度変化量を測定し、測定値差を算出した。結果を表６に示す。 Implemented except that heparin-containing second reagent was used instead of glycerol-containing second reagent, and that the amount of change in absorbance after the lapse of 1 day after setting was measured instead of the amount of change of the absorbance after the lapse of 1 day at the time of setting. In the same manner as in Example 4 (1), the change in absorbance was measured, and the difference in measured values was calculated. The results are shown in Table 6.
（２）シスタチンＣ濃度が約４ｍｇ／Ｌの試料（試料２）の測定
試料１の代わりに、シスタチンＣ濃度が約４ｍｇ／Ｌの試料（試料２）を用いたこと以外は、上記実施例６の（１）と同様にして、測定値差を算出した。結果を表７に示す。
(2) Measurement of a sample (sample 2) having a cystatin C concentration of about 4 mg / L Example 6 except that a sample (sample 2) having a cystatin C concentration of about 4 mg / L was used instead of the sample 1. The measured value difference was calculated in the same manner as (1). The results are shown in Table 7.
上記表６および７の結果から明らかなように、第二試薬に沈降抑制物質（ヘパリンナトリウム）を加えた場合は、沈降抑制物質を加えない場合に比べて、２日経過後の測定値差が格段に小さかった。このことから、沈降抑制物質（ヘパリンナトリウム）を抗体結合金コロイド試薬に添加することで、静置保存時に抗体結合金コロイド粒子の沈降が抑制され、抗体結合金コロイド試薬の均一性が保たれることがわかった。 As is clear from the results in Tables 6 and 7 above, when the precipitation inhibiting substance (sodium heparin) was added to the second reagent, the difference in measured values after 2 days was marked compared to when the precipitation inhibiting substance was not added. It was small. Therefore, by adding a sedimentation inhibitor (heparin sodium) to the antibody-bound gold colloid reagent, the sedimentation of the antibody-bound gold colloid particles is suppressed during storage and the uniformity of the antibody-bound gold colloid reagent is maintained. I understood it.
実施例７：デキストラン硫酸ナトリウムの添加効果（経時変化）
（１）シスタチンＣ濃度が約８ｍｇ／Ｌの試料（試料１）の測定
抗シスタチンＣ抗体結合金コロイド試薬（第二試薬）に、デキストラン硫酸ナトリウムを１％含有するように添加して、デキストラン硫酸含有第二試薬を調製した。
Example 7: Effect of addition of sodium dextran sulfate (time-dependent change)
(1) Measurement of a sample having a cystatin C concentration of about 8 mg / L (sample 1) A dextran sulfate sulfate was added to the anti-cystatin C antibody-conjugated gold colloid reagent (second reagent) so as to contain 1% of dextran sulfate sodium. A containing second reagent was prepared.
グリセロール含有第二試薬の代わりに、デキストラン含有第二試薬を用いたこと、およびセット時１日経過後の吸光度変化量の代わりに、セット時２日経過後、３日経過後、６日経過後、および７日経過後の吸光度変化量を測定したこと以外は、実施例４の（１）と同様にして、吸光度変化量を測定した。得られた吸光度変化量から、既知濃度の標準液で作成した検量線を用いてシスタチンＣ濃度を算出した。結果を表８および図１に示す。 Instead of the glycerol-containing second reagent, the dextran-containing second reagent was used, and instead of the change in absorbance after 1 day at the time of setting, 2 days after the setting, 3 days, 6 days, and 7 days The amount of change in absorbance was measured in the same manner as in Example 4 (1) except that the amount of change in absorbance after the measurement was measured. From the obtained absorbance change amount, the cystatin C concentration was calculated using a calibration curve prepared with a standard solution having a known concentration. The results are shown in Table 8 and FIG.
（２）シスタチンＣ濃度が約４ｍｇ／Ｌの試料（試料２）の測定
試料１の代わりに、シスタチンＣ濃度が約４ｍｇ／Ｌの試料（試料２）を用いたこと以外は、上記実施例７の（１）と同様にして、吸光度変化量を測定し、シスタチンＣ濃度を算出した。結果を表９および図１に示す。
(2) Measurement of a sample (sample 2) having a cystatin C concentration of about 4 mg / L Example 7 except that a sample (sample 2) having a cystatin C concentration of about 4 mg / L was used instead of the sample 1. In the same manner as in (1), the amount of change in absorbance was measured, and the cystatin C concentration was calculated. The results are shown in Table 9 and FIG.
表８および９ならびに図１の結果から明らかなように、第二試薬に沈降抑制物質（デキストラン硫酸ナトリウム）を加えた場合は、特に攪拌しなくても、攪拌した際の測定値と変化なく、７日後まで安定した測定値が得られた。これに対して、沈降抑制物質を加えない場合は、測定前に攪拌し、抗体結合金コロイド粒子濃度を均一にしないと、抗体結合金コロイド粒子が徐々に沈降し、試薬上部の抗体結合金コロイド粒子濃度が薄くなることより、反応系に分注される抗体結合金コロイド粒子量が減少して、日数の経過に伴って測定値が低下した。 As is apparent from the results of Tables 8 and 9 and FIG. 1, when a precipitation inhibitor (sodium dextran sulfate) was added to the second reagent, there was no change in the measured value when stirring, even without particular stirring. Stable measurements were obtained until after 7 days. On the other hand, when no precipitation inhibitor is added, if the antibody-bound gold colloid particles are not evenly mixed, the antibody-bound gold colloid particles will gradually settle, and the antibody-bound gold colloid on top of the reagent. The amount of antibody-bound gold colloidal particles dispensed into the reaction system decreased as the particle concentration decreased, and the measured value decreased with the passage of days.
このことから、抗体結合金コロイド試薬に、沈降抑制物質（デキストラン硫酸ナトリウム）を添加することで、抗体結合金コロイド粒子の沈降が抑制され、試薬中で抗体結合金コロイド粒子濃度を長期にわたり均一に保持できることがわかった。したがって、自動分析装置上に静置したままで攪拌することなく安定した測定値を得ることが可能となる。 Therefore, by adding a sedimentation inhibitor (sodium dextran sulfate) to the antibody-bound gold colloid reagent, sedimentation of the antibody-bound gold colloid particles is suppressed, and the antibody-bound gold colloid particle concentration in the reagent is made uniform over a long period of time. I found that I could hold it. Therefore, it is possible to obtain a stable measurement value without stirring while standing on the automatic analyzer.
実施例９：フェリチン測定用第一試薬の調製
５％塩化ナトリウム、０．２％ＥＤＴＡ、および０．３５％ポリオキシエチレンラウリルエーテルを含む０．５Ｍ ＰＩＰＥＳ（ｐＨ６．５）溶液に反応促進剤としてポリエチレングリコールを１．５〜２．０％程度添加して添加してフェリチン測定用第一試薬とした。
Example 9: Preparation of first reagent for measuring ferritin As a reaction accelerator in 0.5 M PIPES (pH 6.5) solution containing 5% sodium chloride, 0.2% EDTA, and 0.35% polyoxyethylene lauryl ether About 1.5 to 2.0% of polyethylene glycol was added and added as a first reagent for measuring ferritin.
実施例１０：抗フェリチン抗体結合金コロイド試薬（フェリチン測定用第二試薬）の調製
抗フェリチン抗体（ダコ・ジャパン株式会社）を、０．０５％アジ化ナトリウムを含む１０ｍＭ ＨＥＰＥＳ（ｐＨ７．１）で希釈し、５０μｇ／ｍＬの濃度にした。この液１００ｍＬを、実施例１で調製した金コロイド液約１Ｌに加え、冷蔵下で２時間攪拌した。さらに、５．４６％マンニトール、０．５％ＢＳＡ、および０．０５％アジ化ナトリウムを含む１０ｍＭ ＨＥＰＥＳ（ｐＨ７．１）を１１０ｍＬ添加し、３７℃で９０分間攪拌した。次いで、８０００回転で４０分間遠心分離し、上清を除去した後、３％マンニトール、０．１％ＢＳＡ、および０．０５％アジ化ナトリウムを含む５ｍＭ ＨＥＰＥＳ（ｐＨ７．５）（Ａ溶液）を約１Ｌ加え、抗体結合金コロイドを分散させた。さらに、８０００回転で４０分間遠心分離し、上清を除去し、Ａ溶液で抗体感作金コロイドを分散させ、全量を２８０ｍＬとし、抗フェリチン抗体結合金コロイド試薬を得た。
Example 10: Preparation of anti-ferritin antibody-bound colloidal gold reagent (second reagent for ferritin measurement) Anti-ferritin antibody (Dako Japan Co., Ltd.) was added with 10 mM HEPES (pH 7.1) containing 0.05% sodium azide. Diluted to a concentration of 50 μg / mL. 100 mL of this solution was added to about 1 L of the colloidal gold solution prepared in Example 1, and stirred for 2 hours under refrigeration. Further, 110 mL of 10 mM HEPES (pH 7.1) containing 5.46% mannitol, 0.5% BSA, and 0.05% sodium azide was added, and the mixture was stirred at 37 ° C. for 90 minutes. Next, after centrifuging at 8000 rpm for 40 minutes and removing the supernatant, 5 mM HEPES (pH 7.5) (solution A) containing 3% mannitol, 0.1% BSA, and 0.05% sodium azide was added. About 1 L was added to disperse the antibody-bound gold colloid. Further, the mixture was centrifuged at 8000 rpm for 40 minutes, the supernatant was removed, and the antibody-sensitized gold colloid was dispersed with the solution A to make the total volume to 280 mL to obtain an anti-ferritin antibody-bound gold colloid reagent.
実施例１１：デキストラン硫酸ナトリウムの添加効果の検討
(１）フェリチン濃度が約７６０ｎｇ／Ｌの試料（試料４）の測定
抗フェリチン抗体結合金コロイド試薬（第二試薬）に、デキストラン硫酸ナトリウムを０．２％含有するように添加して、デキストラン硫酸０．２％含有第二試薬を調製した。
Example 11: Examination of effect of addition of sodium dextran sulfate
(1) Measurement of a sample (sample 4) having a ferritin concentration of about 760 ng / L To the anti-ferritin antibody-bound gold colloidal reagent (second reagent) so as to contain 0.2% of dextran sulfate sodium, dextran sulfate A second reagent containing 0.2% was prepared.
日立７０７０自動分析装置に、フェリチン濃度が約７６０ｎｇ／Ｌの試料（試料４）、実施例９で調製した第一試薬、および上記デキストラン硫酸０．２％含有第二試薬をそれぞれセットして、以下の条件下でセット時の吸光度変化量を測定した。 In the Hitachi 7070 automatic analyzer, a sample (sample 4) having a ferritin concentration of about 760 ng / L, the first reagent prepared in Example 9, and the second reagent containing 0.2% dextran sulfate were set. The change in absorbance at the time of setting was measured under the above conditions.
（測定条件）
１０μＬの試料４に、第一試薬を１６０μＬ分注し、３７℃で約５分間加温し、次いで、デキストラン硫酸０．２％含有第二試薬を８０μＬ分注し、３７℃で反応した。その後、主波長５０５ｎｍおよび副波長７００ｎｍで測光ポイント１８から３１の二ポイント測定を行って、二ポイント間の吸光度変化量を測定した。なお、吸光度変化量は、上記第二試薬を分注する際に、攪拌しなかった場合（無攪拌吸光度変化量）および予め攪拌した場合（攪拌吸光度変化量）のそれぞれについて測定した。
(Measurement condition)
In 10 μL of
測定した日から２日経過後、４日経過後、および７日経過後において、上記と同様にして、吸光度変化量（無攪拌吸光度変化量および攪拌吸光度変化量）を測定した。 After 2 days, 4 days, and 7 days from the measurement date, the amount of change in absorbance (the amount of change without stirring and the amount of change in stirring absorbance) was measured in the same manner as described above.
得られたセット時、２日経過後、４日経過後、および７日経過後の無攪拌吸光度変化量および攪拌吸光度変化量から、既知濃度の標準液で作成した検量線を用いてフェリチン濃度を算出した。結果を表１０に示す。 The ferritin concentration was calculated from the unstirred absorbance change amount and the stirred absorbance change amount after 2 days, 4 days, and 7 days after the setting, using a calibration curve prepared with a standard solution of a known concentration. The results are shown in Table 10.
他方、デキストラン硫酸０．２％含有第二試薬の代わりに、デキストラン硫酸を１．０％含有する第二試薬、デキストラン硫酸を２．０％含有する第二試薬、または第二試薬をそのまま用いたこと以外は、上記と同様にして、吸光度変化量を測定し、フェリチン濃度を算出した。結果を表１０に併せて示す。なお、デキストラン硫酸を２．０％含有する第二試薬を用いた場合または第二試薬をそのまま用いた場合（コントロール）のフェリチン濃度については、図２に併せて示す。 On the other hand, instead of the second reagent containing 0.2% dextran sulfate, the second reagent containing 1.0% dextran sulfate, the second reagent containing 2.0% dextran sulfate, or the second reagent was used as they were. Except for the above, the change in absorbance was measured and the ferritin concentration was calculated in the same manner as above. The results are also shown in Table 10. The ferritin concentration when using the second reagent containing 2.0% of dextran sulfate or when using the second reagent as it is (control) is also shown in FIG.
（２）フェリチン濃度が約５２０ｎｇ／Ｌの試料（試料５）の測定
試料４の代わりに、フェリチン濃度が約５２０ｎｇ／Ｌの試料（試料５）を用いたこと以外は、上記実施例１１の（１）と同様にして、吸光度変化量を測定し、フェリチン濃度を算出した。結果を表１１に示す。なお、デキストラン硫酸を２．０％含有する第二試薬を用いた場合または第二試薬をそのまま用いた場合（コントロール）のフェリチン濃度については、図２に併せて示す。
(2) Measurement of a sample (sample 5) having a ferritin concentration of about 520 ng / L Instead of
表１０および１１ならびに図２の結果から明らかなように、第二試薬に沈降抑制物質（デキストラン硫酸ナトリウム）を加えた場合は、沈降抑制物質を加えない場合に比べて、２日経過後、４日経過後、および７日経過後の測定値差が格段に小さかった。特にデキストラン硫酸ナトリウム１．０％含有第二試薬および２．０％含有第二試薬を用いた場合、７日経過後においても、測定前に抗体結合金コロイド試薬を攪拌しなかった場合の測定値と、攪拌した際の測定値との差が全くなかった。沈降抑制物質を加えない場合は、測定前に攪拌し、抗体結合金コロイド粒子濃度を均一にしないと、抗体結合金コロイド粒子が徐々に沈降し、試薬上部の抗体結合金コロイド粒子濃度が薄くなり、反応系に分注される抗体結合金コロイド粒子量が減少して日数の経過に伴って測定値が低下した。 As is apparent from the results of Tables 10 and 11 and FIG. 2, when a precipitation inhibitor (sodium dextran sulfate) was added to the second reagent, 4 days later, compared to the case where no precipitation inhibitor was added. The difference in measured values after the past and after 7 days was remarkably small. In particular, when the second reagent containing 1.0% dextran sulfate and the second reagent containing 2.0% were used, the measured value when the antibody-bound gold colloid reagent was not stirred before the measurement even after 7 days had passed. There was no difference from the measured value when stirring. If no anti-sedimentation substance is added, stirring is performed before measurement, and unless the antibody-bound gold colloid particle concentration is uniform, the antibody-bound gold colloid particles gradually settle, and the antibody-bound gold colloid particle concentration on the top of the reagent becomes thin. The amount of antibody-bound gold colloid particles dispensed into the reaction system decreased, and the measured value decreased with the passage of days.
このことから、抗体結合金コロイド試薬に沈降抑制物質（デキストラン硫酸ナトリウム）を添加することで、抗体結合金コロイド粒子の沈降が抑制され、試薬中で抗体結合金コロイド粒子濃度を長期にわたり均一に保持できることがわかった。したがって、自動分析装置上に静置したままで攪拌することなく安定した測定値を得ることができることが可能となる。 Therefore, by adding a sedimentation inhibitor (sodium dextran sulfate) to the antibody-bound gold colloid reagent, the sedimentation of the antibody-bound gold colloidal particles is suppressed, and the antibody-bound gold colloidal particle concentration in the reagent is kept uniform over a long period I knew it was possible. Therefore, it is possible to obtain a stable measurement value without stirring while standing on the automatic analyzer.
本発明によれば、反応性物質結合微小粒子の沈降を抑制することができる。したがって、該微小粒子の沈降が抑制された試薬の提供が可能となる。この試薬は、該微小粒子の濃度が長期にわたり均一に保持される。そのため、例えば、この試薬を用いて免疫測定を行う場合には、該試薬を攪拌せずとも、反応性物質結合微小粒子を最終反応液に等量分注することができるため、誤差の少ない安定した測定値を得ることが可能となる。これにより、測定者にとって大変な負担となっていた、煩雑な攪拌操作の必要性を無くすとともに、攪拌操作を怠ったことから生じる測定誤差およびそれによる臨床判断ミスを防ぐことができる。この試薬および該試薬を含む試薬キットは、特に自動化免疫装置に有用である。 According to the present invention, sedimentation of reactive substance-bound microparticles can be suppressed. Therefore, it is possible to provide a reagent in which sedimentation of the fine particles is suppressed. This reagent keeps the concentration of the microparticles uniform over a long period of time. Therefore, for example, when immunoassay is performed using this reagent, it is possible to dispense an equal amount of reactive substance-bound microparticles into the final reaction solution without stirring the reagent. Measured values can be obtained. As a result, it is possible to eliminate the need for a complicated stirring operation, which has been a heavy burden on the measurer, and to prevent measurement errors and clinical judgment errors resulting from the failure of the stirring operation. This reagent and a reagent kit containing the reagent are particularly useful for automated immune devices.
Claims (4)
該金コロイド粒子の分散液中に、デキストラン硫酸またはその塩を０．３〜５質量％の割合で共存させる工程を含む、方法。 A method for suppressing sedimentation of colloidal gold particles to which an antibody or antigen is bound ,
The dispersion of the colloidal gold particles, comprising the step of co dextran sulfate or a salt thereof in a proportion of 0.3 to 5% by weight, method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005307879A JP5442179B2 (en) | 2005-10-21 | 2005-10-21 | Method for suppressing sedimentation of fine particles bound with reactive substance and reagent containing the fine particles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005307879A JP5442179B2 (en) | 2005-10-21 | 2005-10-21 | Method for suppressing sedimentation of fine particles bound with reactive substance and reagent containing the fine particles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007114129A JP2007114129A (en) | 2007-05-10 |
| JP2007114129A5 JP2007114129A5 (en) | 2008-10-16 |
| JP5442179B2 true JP5442179B2 (en) | 2014-03-12 |
Family
ID=38096448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005307879A Active JP5442179B2 (en) | 2005-10-21 | 2005-10-21 | Method for suppressing sedimentation of fine particles bound with reactive substance and reagent containing the fine particles |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5442179B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104535756A (en) * | 2008-07-04 | 2015-04-22 | 积水医疗株式会社 | Method for enhancing sensitivity or method for avoiding influence of hemoglobin in immunological measurement |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1980853A1 (en) * | 2007-04-11 | 2008-10-15 | Alfresa Pharma Corporation | Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle |
| JP5364310B2 (en) * | 2008-07-14 | 2013-12-11 | アルフレッサファーマ株式会社 | Method for stabilizing microparticles to which reactive substances are bound, and reagent containing the microparticles |
| US9034656B2 (en) | 2011-11-21 | 2015-05-19 | Abaxis, Inc. | Signal amplification in lateral flow and related immunoassays |
| JP6303313B2 (en) * | 2013-07-26 | 2018-04-04 | コニカミノルタ株式会社 | Reagent bottles for aqueous dispersions, pathological stains and automatic stainers |
| JP6406253B2 (en) * | 2013-07-26 | 2018-10-17 | コニカミノルタ株式会社 | Pathological stain |
| JP6394100B2 (en) * | 2014-06-19 | 2018-09-26 | 不二製油株式会社 | Soy protein material for protein enhancement of breads |
| TWI691716B (en) | 2014-08-13 | 2020-04-21 | 美商艾巴希斯公司 | Signal amplification in plasmonic specific-binding partner assays |
| AU2016301375B2 (en) * | 2015-08-04 | 2022-03-03 | Zoetis Services Llc | Signal amplification in solution-based plasmonic specific-binding partner assays |
| KR102486615B1 (en) | 2017-01-30 | 2023-01-11 | 조에티스 서비시즈 엘엘씨 | Solution-based plasmon specific-binding partner assay and metallic nanostructures |
| US11452783B2 (en) | 2017-02-14 | 2022-09-27 | Gi Supply | Tissue stain and use thereof |
| CN112051401B (en) * | 2020-08-28 | 2022-09-06 | 武汉生之源生物科技股份有限公司 | Pepsinogen's assay kit |
| WO2023190275A1 (en) * | 2022-03-28 | 2023-10-05 | 積水メディカル株式会社 | Latex particle dispersion liquid |
| CN115856319B (en) * | 2022-11-30 | 2023-07-28 | 中拓生物有限公司 | Soluble growth stimulation expressed gene 2 protein determination kit, and preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3004426B2 (en) * | 1991-11-12 | 2000-01-31 | 日本製粉株式会社 | Pet food |
| JP3266960B2 (en) * | 1993-01-13 | 2002-03-18 | 和光純薬工業株式会社 | Immunoassay using colloidal gold particles |
| DE69527877T2 (en) * | 1994-04-29 | 2003-04-30 | Seradyn Inc | Microparticle immunoassay reagents, sensitive and specific immunoassay reagents and immunoassay method |
| JP2545707B2 (en) * | 1995-01-04 | 1996-10-23 | 日東電工株式会社 | Immunological diagnostic reagent |
| JP2004325192A (en) * | 2003-04-23 | 2004-11-18 | Azwell Inc | Measuring method and measuring kit of hapten by gold colloid aggregation method |
-
2005
- 2005-10-21 JP JP2005307879A patent/JP5442179B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104535756A (en) * | 2008-07-04 | 2015-04-22 | 积水医疗株式会社 | Method for enhancing sensitivity or method for avoiding influence of hemoglobin in immunological measurement |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007114129A (en) | 2007-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5442179B2 (en) | Method for suppressing sedimentation of fine particles bound with reactive substance and reagent containing the fine particles | |
| US7867785B2 (en) | Carrier particle latex for assay reagent and assay reagent | |
| JP5364310B2 (en) | Method for stabilizing microparticles to which reactive substances are bound, and reagent containing the microparticles | |
| WO2010021399A1 (en) | Cystatin c adsorption inhibitor | |
| JP3851807B2 (en) | Method for suppressing prozone phenomenon in immune reaction and reagent for measuring immune reaction | |
| WO2010047163A1 (en) | Method and reagent kit for immunological measurement | |
| JPH06300761A (en) | Reagent and method for immunonephelometry | |
| JP5328665B2 (en) | Method and kit for measuring acrolein adduct of specimen using agglutination reaction of immunological microparticles | |
| JP2005283250A (en) | Measuring method of gold colloid agglutination reaction | |
| EP1980853A1 (en) | Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle | |
| JP3266960B2 (en) | Immunoassay using colloidal gold particles | |
| US20080261328A1 (en) | Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle | |
| JP4454885B2 (en) | Immunoassay method and reagent therefor | |
| CN101266244A (en) | Settlement inhibiting method of tiny particle for binding reactive substance and the reagent | |
| WO2010013525A1 (en) | Method of assaying complex and kit to be used therefor | |
| JP4982107B2 (en) | Method of measuring specimen using agglutination reaction of immunological microparticles and kit for measurement | |
| JP3471198B2 (en) | Reagent for turbidimetric determination of immunological latex | |
| JP2004325414A (en) | Method and kit for measuring immunity | |
| JP5586232B2 (en) | Method and kit for immunological measurement of specimen using agglutination reaction of microparticles | |
| JP4507439B2 (en) | Latex immunoturbidimetric assay and kit used therefor | |
| JPH02103466A (en) | Method for measuring immunological active material and reagent for said method | |
| JP2000146974A (en) | Immunoassay | |
| JPH10253629A (en) | Production of immunoassay reagent | |
| JPH08278308A (en) | Immunoassay method | |
| JPH11201970A (en) | Manufacture of immunity measuring reagent and immunity measuring method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080829 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080829 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100723 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100927 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100927 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110112 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111014 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111014 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111108 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120127 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20130513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131024 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131218 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5442179 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |